JP2022513449A - 新規な甲状腺模倣物 - Google Patents
新規な甲状腺模倣物 Download PDFInfo
- Publication number
- JP2022513449A JP2022513449A JP2021533331A JP2021533331A JP2022513449A JP 2022513449 A JP2022513449 A JP 2022513449A JP 2021533331 A JP2021533331 A JP 2021533331A JP 2021533331 A JP2021533331 A JP 2021533331A JP 2022513449 A JP2022513449 A JP 2022513449A
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutically acceptable
- compound according
- fibrosis
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001685 thyroid gland Anatomy 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 240
- 150000003839 salts Chemical class 0.000 claims abstract description 166
- 238000000034 method Methods 0.000 claims abstract description 107
- 239000012453 solvate Substances 0.000 claims abstract description 103
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 91
- 201000010099 disease Diseases 0.000 claims abstract description 76
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 28
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 21
- 230000003176 fibrotic effect Effects 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 162
- 125000000217 alkyl group Chemical group 0.000 claims description 96
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 56
- 206010016654 Fibrosis Diseases 0.000 claims description 50
- 230000004761 fibrosis Effects 0.000 claims description 48
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 41
- 208000016192 Demyelinating disease Diseases 0.000 claims description 36
- 201000006417 multiple sclerosis Diseases 0.000 claims description 35
- -1 hydrate Substances 0.000 claims description 31
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 23
- 125000003342 alkenyl group Chemical group 0.000 claims description 23
- 125000000623 heterocyclic group Chemical group 0.000 claims description 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 22
- 230000027455 binding Effects 0.000 claims description 19
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 17
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 16
- 125000001188 haloalkyl group Chemical group 0.000 claims description 16
- 230000004770 neurodegeneration Effects 0.000 claims description 16
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 15
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 15
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 15
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 15
- 208000020832 chronic kidney disease Diseases 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 15
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 208000034189 Sclerosis Diseases 0.000 claims description 13
- 208000010796 X-linked adrenoleukodystrophy Diseases 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 13
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- 230000002757 inflammatory effect Effects 0.000 claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 206010035664 Pneumonia Diseases 0.000 claims description 11
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 208000034800 Leukoencephalopathies Diseases 0.000 claims description 10
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims description 10
- 230000001684 chronic effect Effects 0.000 claims description 10
- 230000036541 health Effects 0.000 claims description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- 230000000750 progressive effect Effects 0.000 claims description 10
- 208000024985 Alport syndrome Diseases 0.000 claims description 9
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims description 9
- 230000007812 deficiency Effects 0.000 claims description 9
- 208000003215 hereditary nephritis Diseases 0.000 claims description 9
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 claims description 9
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 9
- 239000000377 silicon dioxide Substances 0.000 claims description 9
- 208000034799 Tauopathies Diseases 0.000 claims description 8
- 230000002490 cerebral effect Effects 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 230000003210 demyelinating effect Effects 0.000 claims description 8
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 8
- 230000002018 overexpression Effects 0.000 claims description 8
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 8
- 231100000241 scar Toxicity 0.000 claims description 8
- 208000006011 Stroke Diseases 0.000 claims description 7
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 7
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 7
- 206010008129 cerebral palsy Diseases 0.000 claims description 7
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 7
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 7
- 208000036546 leukodystrophy Diseases 0.000 claims description 7
- 230000023105 myelination Effects 0.000 claims description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 7
- 208000011403 Alexander disease Diseases 0.000 claims description 6
- 208000006829 Allan-Herndon-Dudley syndrome Diseases 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 6
- 206010010252 Concentric sclerosis Diseases 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 6
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims description 6
- 206010030113 Oedema Diseases 0.000 claims description 6
- 206010033799 Paralysis Diseases 0.000 claims description 6
- 206010063493 Premature ageing Diseases 0.000 claims description 6
- 208000032038 Premature aging Diseases 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 206010061811 demyelinating polyneuropathy Diseases 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 206010065579 multifocal motor neuropathy Diseases 0.000 claims description 6
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 6
- 201000001119 neuropathy Diseases 0.000 claims description 6
- 230000007823 neuropathy Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 6
- 230000000241 respiratory effect Effects 0.000 claims description 6
- 230000001148 spastic effect Effects 0.000 claims description 6
- 230000008733 trauma Effects 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 206010003694 Atrophy Diseases 0.000 claims description 5
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 5
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 5
- 208000003926 Myelitis Diseases 0.000 claims description 5
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 5
- 206010039710 Scleroderma Diseases 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 230000037444 atrophy Effects 0.000 claims description 5
- 208000006454 hepatitis Diseases 0.000 claims description 5
- 231100000283 hepatitis Toxicity 0.000 claims description 5
- 230000002123 temporal effect Effects 0.000 claims description 5
- 201000010374 Down Syndrome Diseases 0.000 claims description 4
- 208000028782 Hereditary disease Diseases 0.000 claims description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 4
- 208000024556 Mendelian disease Diseases 0.000 claims description 4
- 206010044688 Trisomy 21 Diseases 0.000 claims description 4
- 210000000349 chromosome Anatomy 0.000 claims description 4
- 210000002435 tendon Anatomy 0.000 claims description 4
- 210000004885 white matter Anatomy 0.000 claims description 4
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 3
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 3
- 208000014085 Chronic respiratory disease Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 229920000742 Cotton Polymers 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010048768 Dermatosis Diseases 0.000 claims description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 3
- 206010014961 Eosinophilic myocarditis Diseases 0.000 claims description 3
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 3
- 208000031071 Hamman-Rich Syndrome Diseases 0.000 claims description 3
- 208000018565 Hemochromatosis Diseases 0.000 claims description 3
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 3
- 206010021263 IgA nephropathy Diseases 0.000 claims description 3
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims description 3
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010072877 Intestinal fibrosis Diseases 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 208000004852 Lung Injury Diseases 0.000 claims description 3
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims description 3
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 3
- 206010028289 Muscle atrophy Diseases 0.000 claims description 3
- 208000037159 Nager syndrome Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 3
- 206010034010 Parkinsonism Diseases 0.000 claims description 3
- 208000004362 Penile Induration Diseases 0.000 claims description 3
- 208000020758 Peyronie disease Diseases 0.000 claims description 3
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims description 3
- 208000017442 Retinal disease Diseases 0.000 claims description 3
- 206010038923 Retinopathy Diseases 0.000 claims description 3
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims description 3
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010067269 Uterine fibrosis Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 201000011032 Werner Syndrome Diseases 0.000 claims description 3
- 208000018839 Wilson disease Diseases 0.000 claims description 3
- 208000026589 Wolman disease Diseases 0.000 claims description 3
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 3
- 201000004073 acute interstitial pneumonia Diseases 0.000 claims description 3
- 239000010425 asbestos Substances 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 230000009787 cardiac fibrosis Effects 0.000 claims description 3
- 208000018631 connective tissue disease Diseases 0.000 claims description 3
- 230000008602 contraction Effects 0.000 claims description 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 3
- 239000000428 dust Substances 0.000 claims description 3
- 230000002357 endometrial effect Effects 0.000 claims description 3
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims description 3
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 3
- 208000014188 hereditary optic neuropathy Diseases 0.000 claims description 3
- 206010020718 hyperplasia Diseases 0.000 claims description 3
- 230000002390 hyperplastic effect Effects 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 231100000515 lung injury Toxicity 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 230000020763 muscle atrophy Effects 0.000 claims description 3
- 201000000585 muscular atrophy Diseases 0.000 claims description 3
- 206010028537 myelofibrosis Diseases 0.000 claims description 3
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 claims description 3
- 230000009788 parenchymal fibrosis Effects 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 208000037244 polycythemia vera Diseases 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 208000034979 restrictive dermopathy Diseases 0.000 claims description 3
- 230000002207 retinal effect Effects 0.000 claims description 3
- 229910052895 riebeckite Inorganic materials 0.000 claims description 3
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 3
- 230000009758 senescence Effects 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 206010058029 Arthrofibrosis Diseases 0.000 claims description 2
- 206010028594 Myocardial fibrosis Diseases 0.000 claims description 2
- 208000037280 Trisomy Diseases 0.000 claims description 2
- 230000001746 atrial effect Effects 0.000 claims description 2
- 208000037999 tubulointerstitial fibrosis Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims 8
- 125000001475 halogen functional group Chemical group 0.000 claims 7
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims 6
- 208000032544 Cicatrix Diseases 0.000 claims 3
- 230000037387 scars Effects 0.000 claims 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 206010036805 Progressive massive fibrosis Diseases 0.000 claims 2
- 206010050207 Skin fibrosis Diseases 0.000 claims 2
- 208000000491 Tendinopathy Diseases 0.000 claims 2
- 206010043255 Tendonitis Diseases 0.000 claims 2
- 102000004142 Trypsin Human genes 0.000 claims 2
- 108090000631 Trypsin Proteins 0.000 claims 2
- 230000001919 adrenal effect Effects 0.000 claims 2
- 238000002845 discoloration Methods 0.000 claims 2
- 208000007345 glycogen storage disease Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 201000010901 lateral sclerosis Diseases 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 230000003589 nefrotoxic effect Effects 0.000 claims 2
- 230000002988 nephrogenic effect Effects 0.000 claims 2
- 231100000381 nephrotoxic Toxicity 0.000 claims 2
- 201000004415 tendinitis Diseases 0.000 claims 2
- 239000012588 trypsin Substances 0.000 claims 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 208000019291 X-linked disease Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 210000005239 tubule Anatomy 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 5
- 238000010586 diagram Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 220
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 134
- 235000019439 ethyl acetate Nutrition 0.000 description 109
- 239000000543 intermediate Substances 0.000 description 76
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 74
- 230000015572 biosynthetic process Effects 0.000 description 64
- 239000003208 petroleum Substances 0.000 description 64
- 238000003786 synthesis reaction Methods 0.000 description 64
- 239000000243 solution Substances 0.000 description 57
- 238000004809 thin layer chromatography Methods 0.000 description 57
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 56
- 238000005481 NMR spectroscopy Methods 0.000 description 56
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 50
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 239000011734 sodium Substances 0.000 description 43
- 239000007787 solid Substances 0.000 description 43
- 239000012267 brine Substances 0.000 description 40
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 40
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 239000000460 chlorine Substances 0.000 description 30
- 239000012074 organic phase Substances 0.000 description 30
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 27
- 125000005843 halogen group Chemical group 0.000 description 26
- 230000002829 reductive effect Effects 0.000 description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 22
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 22
- 238000002953 preparative HPLC Methods 0.000 description 22
- 238000012360 testing method Methods 0.000 description 21
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 20
- 102100033451 Thyroid hormone receptor beta Human genes 0.000 description 18
- 239000002253 acid Substances 0.000 description 18
- 125000003118 aryl group Chemical group 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
- CRBJBYGJVIBWIY-UHFFFAOYSA-N 2-isopropylphenol Chemical compound CC(C)C1=CC=CC=C1O CRBJBYGJVIBWIY-UHFFFAOYSA-N 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 14
- 239000012043 crude product Substances 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 229910052799 carbon Chemical group 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 10
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 10
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 10
- 239000000556 agonist Substances 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 229940036555 thyroid hormone Drugs 0.000 description 9
- 239000005495 thyroid hormone Substances 0.000 description 9
- 102000004217 thyroid hormone receptors Human genes 0.000 description 9
- 108090000721 thyroid hormone receptors Proteins 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 8
- 239000012298 atmosphere Substances 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 239000012230 colorless oil Substances 0.000 description 8
- 125000001072 heteroaryl group Chemical group 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 240000007594 Oryza sativa Species 0.000 description 6
- 235000007164 Oryza sativa Nutrition 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 229940125797 compound 12 Drugs 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000012746 preparative thin layer chromatography Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000009566 rice Nutrition 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 5
- 206010012305 Demyelination Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 150000001412 amines Chemical group 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 125000004149 thio group Chemical group *S* 0.000 description 5
- 239000011592 zinc chloride Substances 0.000 description 5
- 235000005074 zinc chloride Nutrition 0.000 description 5
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 4
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 4
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 4
- ZWMOEOUOSHGSAM-UHFFFAOYSA-N 2-[3-bromo-4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-5-methylphenoxy]-N-methylacetamide Chemical compound BrC=1C=C(OCC(=O)NC)C=C(C=1CC1=CC(=C(C=C1)O)C(C)C)C ZWMOEOUOSHGSAM-UHFFFAOYSA-N 0.000 description 4
- KAGPPNDTWJZEOQ-UHFFFAOYSA-N 2-[3-chloro-5-ethyl-4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]phenoxy]acetic acid Chemical compound C(OC1=CC(=C(CC2=CC=C(O)C(C(C)C)=C2)C(Cl)=C1)CC)C(=O)O KAGPPNDTWJZEOQ-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 4
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 229940126208 compound 22 Drugs 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 150000002989 phenols Chemical class 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 229960001603 tamoxifen Drugs 0.000 description 4
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 4
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- CPYASDNZXCBRDL-UHFFFAOYSA-N 2-[3-chloro-5-ethyl-4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]phenoxy]-N,N-dimethylacetamide Chemical compound O(CC(=O)N(C)C)C1=CC(=C(CC2=CC(=C(O)C=C2)C(C)C)C(=C1)Cl)CC CPYASDNZXCBRDL-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 description 3
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- QNAZTOHXCZPOSA-UHFFFAOYSA-N Sobetirome Chemical compound C1=C(O)C(C(C)C)=CC(CC=2C(=CC(OCC(O)=O)=CC=2C)C)=C1 QNAZTOHXCZPOSA-UHFFFAOYSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001721 carbon Chemical class 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 229940125961 compound 24 Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000003007 myelin sheath Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- DPGSPRJLAZGUBQ-UHFFFAOYSA-N 2-ethenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OB(C=C)OC1(C)C DPGSPRJLAZGUBQ-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- WUKDATVIQYXCPY-UHFFFAOYSA-N 2-sulfonylethanamine Chemical compound NCC=S(=O)=O WUKDATVIQYXCPY-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- GMGWXLPFRHYWAS-UHFFFAOYSA-N 3-bromo-5-chlorophenol Chemical compound OC1=CC(Cl)=CC(Br)=C1 GMGWXLPFRHYWAS-UHFFFAOYSA-N 0.000 description 2
- OTUYBYTUBWJBLO-UHFFFAOYSA-N 3-bromo-5-methylphenol Chemical compound CC1=CC(O)=CC(Br)=C1 OTUYBYTUBWJBLO-UHFFFAOYSA-N 0.000 description 2
- QXHZLCYUCTZZNL-UHFFFAOYSA-N 3-chloro-5-methylphenol Chemical compound CC1=CC(O)=CC(Cl)=C1 QXHZLCYUCTZZNL-UHFFFAOYSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000022526 Canavan disease Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-IGMARMGPSA-N Carbon-12 Chemical compound [12C] OKTJSMMVPCPJKN-IGMARMGPSA-N 0.000 description 2
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 2
- 206010071068 Clinically isolated syndrome Diseases 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 108010001515 Galectin 4 Proteins 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010028570 Myelopathy Diseases 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- LRHVEGCJASOOIG-UHFFFAOYSA-N acetic acid;bromoethane Chemical compound CCBr.CC(O)=O LRHVEGCJASOOIG-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000005602 azabenzimidazolyl group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 125000000950 dibromo group Chemical group Br* 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 210000000585 glomerular basement membrane Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- QABLOFMHHSOFRJ-UHFFFAOYSA-N methyl 2-chloroacetate Chemical compound COC(=O)CCl QABLOFMHHSOFRJ-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 150000002825 nitriles Chemical group 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 201000002793 renal fibrosis Diseases 0.000 description 2
- 238000003571 reporter gene assay Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000000101 thioether group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 150000004669 very long chain fatty acids Chemical class 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DAXJNUBSBFUTRP-RTQNCGMRSA-N (8r,9s,10r,13s,14s)-6-(hydroxymethyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(CO)C2=C1 DAXJNUBSBFUTRP-RTQNCGMRSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- OBHCCORLMBZISY-UHFFFAOYSA-N 2,3-dimethylbutane-2,3-diol;ethenylboronic acid Chemical compound OB(O)C=C.CC(C)(O)C(C)(C)O OBHCCORLMBZISY-UHFFFAOYSA-N 0.000 description 1
- OXNRVEZUVANMDS-UHFFFAOYSA-N 2-[3-bromo-4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-5-methylphenoxy]acetic acid Chemical compound BrC=1C=C(OCC(=O)O)C=C(C=1CC1=CC(=C(C=C1)O)C(C)C)C OXNRVEZUVANMDS-UHFFFAOYSA-N 0.000 description 1
- KMAFXLLQNLCOBD-UHFFFAOYSA-N 2-[3-chloro-4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-5-(trifluoromethyl)phenoxy]acetic acid Chemical compound O(CC(=O)O)C1=CC(=C(CC2=CC(=C(O)C=C2)C(C)C)C(C(F)(F)F)=C1)Cl KMAFXLLQNLCOBD-UHFFFAOYSA-N 0.000 description 1
- HWMFTDSLTXHHGA-UHFFFAOYSA-N 2-[3-chloro-4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-5-methylphenoxy]-N-methylacetamide Chemical compound ClC=1C=C(OCC(=O)NC)C=C(C=1CC1=CC(=C(C=C1)O)C(C)C)C HWMFTDSLTXHHGA-UHFFFAOYSA-N 0.000 description 1
- SWFVYZNKQFAHAJ-UHFFFAOYSA-N 2-[3-chloro-4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-5-methylphenoxy]acetic acid Chemical compound ClC=1C=C(OCC(=O)O)C=C(C=1CC1=CC(=C(C=C1)O)C(C)C)C SWFVYZNKQFAHAJ-UHFFFAOYSA-N 0.000 description 1
- LOFCYPPFGSZZEL-UHFFFAOYSA-N 2-[3-chloro-4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-5-prop-1-en-2-ylphenoxy]-N,N-dimethylacetamide Chemical compound O(CC(=O)N(C)C)C1=CC(=C(CC2=CC(=C(O)C=C2)C(C)C)C(C(=C)C)=C1)Cl LOFCYPPFGSZZEL-UHFFFAOYSA-N 0.000 description 1
- GISHSMOYXHRGBS-UHFFFAOYSA-N 2-[3-chloro-4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-5-prop-1-en-2-ylphenoxy]-N-methylacetamide Chemical compound O(CC(=O)NC)C1=CC(C(=C)C)=C(C(=C1)Cl)CC1=CC(=C(O)C=C1)C(C)C GISHSMOYXHRGBS-UHFFFAOYSA-N 0.000 description 1
- AQGKEZNSUBIHAA-UHFFFAOYSA-N 2-[3-chloro-4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-5-prop-1-en-2-ylphenoxy]acetic acid Chemical compound O(CC(=O)O)C1=CC(C(=C)C)=C(CC2=CC=C(O)C(C(C)C)=C2)C(=C1)Cl AQGKEZNSUBIHAA-UHFFFAOYSA-N 0.000 description 1
- ILTNESRNYIKCNC-UHFFFAOYSA-N 2-[3-chloro-4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-5-prop-1-en-2-ylphenoxy]acetyl chloride Chemical compound C(OC1=CC(C(=C)C)=C(C(=C1)Cl)CC1=CC(=C(O)C=C1)C(C)C)C(=O)Cl ILTNESRNYIKCNC-UHFFFAOYSA-N 0.000 description 1
- CDGGACSFFVZTEQ-UHFFFAOYSA-N 2-[3-chloro-4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-5-propan-2-ylphenoxy]-N,N-dimethylacetamide Chemical compound O=C(COC1=CC(=C(CC2=CC(=C(O)C=C2)C(C)C)C(=C1)Cl)C(C)C)N(C)C CDGGACSFFVZTEQ-UHFFFAOYSA-N 0.000 description 1
- AQSWOHJZALPQEQ-UHFFFAOYSA-N 2-[3-chloro-4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-5-propan-2-ylphenoxy]-N-methylacetamide Chemical compound O(CC(=O)NC)C1=CC(=C(CC2=CC(=C(O)C=C2)C(C)C)C(=C1)Cl)C(C)C AQSWOHJZALPQEQ-UHFFFAOYSA-N 0.000 description 1
- YMXVOZZPBFTJPK-UHFFFAOYSA-N 2-[3-chloro-4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-5-propan-2-ylphenoxy]acetic acid Chemical compound O(CC(=O)O)C1=CC(=C(CC2=CC(=C(O)C=C2)C(C)C)C(=C1)Cl)C(C)C YMXVOZZPBFTJPK-UHFFFAOYSA-N 0.000 description 1
- WJCOHHZBIDDVPU-UHFFFAOYSA-N 2-[3-cyclopropyl-4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-5-methylphenoxy]acetic acid Chemical compound O(CC(=O)O)C1=CC(=C(CC2=CC(=C(O)C=C2)C(C)C)C(C2CC2)=C1)C WJCOHHZBIDDVPU-UHFFFAOYSA-N 0.000 description 1
- BPUJSMAQDNGXRM-UHFFFAOYSA-N 2-[3-ethenyl-4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-5-methylphenoxy]acetic acid Chemical compound C(C(=O)O)OC1=CC(=C(CC2=CC=C(O)C(C(C)C)=C2)C(=C1)C)C=C BPUJSMAQDNGXRM-UHFFFAOYSA-N 0.000 description 1
- QOZWELMEFYDJRR-UHFFFAOYSA-N 2-[3-ethyl-4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-5-methylphenoxy]acetic acid Chemical compound C(C(=O)O)OC1=CC(=C(CC2=CC=C(O)C(C(C)C)=C2)C(=C1)C)CC QOZWELMEFYDJRR-UHFFFAOYSA-N 0.000 description 1
- ALPWVALDIUDEKX-UHFFFAOYSA-N 2-[4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-3-methyl-5-(trifluoromethyl)phenoxy]acetic acid Chemical compound C(OC1=CC(=C(CC2=CC(=C(O)C=C2)C(C)C)C(=C1)C)C(F)(F)F)C(=O)O ALPWVALDIUDEKX-UHFFFAOYSA-N 0.000 description 1
- FAECGIONPLVIFE-UHFFFAOYSA-N 2-[4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-3-methyl-5-prop-1-en-2-ylphenoxy]acetic acid Chemical compound C(OC1=CC(=C(C(=C1)C)CC1=CC=C(O)C(C(C)C)=C1)C(=C)C)C(=O)O FAECGIONPLVIFE-UHFFFAOYSA-N 0.000 description 1
- WVDCICSENAOYRH-UHFFFAOYSA-N 2-[4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-3-methyl-5-propan-2-ylphenoxy]acetic acid Chemical compound C(OC1=CC(=C(CC2=CC(=C(O)C=C2)C(C)C)C(=C1)C)C(C)C)C(=O)O WVDCICSENAOYRH-UHFFFAOYSA-N 0.000 description 1
- GJQAQKAYZJREAX-UHFFFAOYSA-N 2-[4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-3-methyl-5-propylphenoxy]acetic acid Chemical compound O(CC(=O)O)C1=CC(=C(CC2=CC=C(O)C(C(C)C)=C2)C(=C1)C)CCC GJQAQKAYZJREAX-UHFFFAOYSA-N 0.000 description 1
- NUVOUOHXOKZTQW-UHFFFAOYSA-N 2-[[1-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-2-methylindol-4-yl]amino]-2-oxoacetic acid Chemical compound C1=C(O)C(C(C)C)=CC(CN2C3=CC=CC(NC(=O)C(O)=O)=C3C=C2C)=C1 NUVOUOHXOKZTQW-UHFFFAOYSA-N 0.000 description 1
- QOWDVYZPDZEOEA-UHFFFAOYSA-N 2-[[1-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-7-methylindol-4-yl]amino]-2-oxoacetic acid Chemical compound C1=C(O)C(C(C)C)=CC(CN2C3=C(C)C=CC(NC(=O)C(O)=O)=C3C=C2)=C1 QOWDVYZPDZEOEA-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- JVBPAIKIXXJNLM-UHFFFAOYSA-N 3-bromo-4-(hydroxymethyl)-5-methylphenol Chemical compound Cc1cc(O)cc(Br)c1CO JVBPAIKIXXJNLM-UHFFFAOYSA-N 0.000 description 1
- ARUHVGOYMQAHJU-UHFFFAOYSA-N 3-bromo-5-chloro-4-(hydroxymethyl)phenol Chemical compound OCC1=C(Cl)C=C(O)C=C1Br ARUHVGOYMQAHJU-UHFFFAOYSA-N 0.000 description 1
- BQXVWCOZRMGRNO-UHFFFAOYSA-N 3-chloro-4-(hydroxymethyl)-5-(trifluoromethyl)phenol Chemical compound C1(Cl)=C(CO)C(C(F)(F)F)=CC(O)=C1 BQXVWCOZRMGRNO-UHFFFAOYSA-N 0.000 description 1
- YXKQICHRDDFECC-UHFFFAOYSA-N 3-chloro-4-(hydroxymethyl)-5-methylphenol Chemical compound ClC=1C=C(C=C(C=1CO)C)O YXKQICHRDDFECC-UHFFFAOYSA-N 0.000 description 1
- BPJWMOPEHPOKFT-UHFFFAOYSA-N 3-chloro-5-(trifluoromethyl)phenol Chemical compound OC1=CC(Cl)=CC(C(F)(F)F)=C1 BPJWMOPEHPOKFT-UHFFFAOYSA-N 0.000 description 1
- AOEBDRMJSVRXAC-UHFFFAOYSA-N 3-chloro-5-ethenylphenol Chemical compound Oc1cc(Cl)cc(C=C)c1 AOEBDRMJSVRXAC-UHFFFAOYSA-N 0.000 description 1
- CLUPGYDSOVLWTI-UHFFFAOYSA-N 3-chloro-5-ethyl-4-(hydroxymethyl)phenol Chemical compound ClC1=C(CO)C(CC)=CC(O)=C1 CLUPGYDSOVLWTI-UHFFFAOYSA-N 0.000 description 1
- TVXPDDBBCZWBIE-UHFFFAOYSA-N 3-chloro-5-ethylphenol Chemical compound CCC1=CC(O)=CC(Cl)=C1 TVXPDDBBCZWBIE-UHFFFAOYSA-N 0.000 description 1
- WYDJMBLMXGCHOL-UHFFFAOYSA-N 3-methyl-5-(trifluoromethyl)aniline Chemical compound CC1=CC(N)=CC(C(F)(F)F)=C1 WYDJMBLMXGCHOL-UHFFFAOYSA-N 0.000 description 1
- VOOZRDXCKRUKTQ-UHFFFAOYSA-N 3-methyl-5-(trifluoromethyl)phenol Chemical compound CC1=CC(O)=CC(C(F)(F)F)=C1 VOOZRDXCKRUKTQ-UHFFFAOYSA-N 0.000 description 1
- COPMASWDWLENMV-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-prop-1-enyl-1,3,2-dioxaborolane Chemical compound CC=CB1OC(C)(C)C(C)(C)O1 COPMASWDWLENMV-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SPYOYOMYCMZYIV-UHFFFAOYSA-N 4-(hydroxymethyl)-3-methyl-5-(trifluoromethyl)phenol Chemical compound C1(=C(C=C(C=C1C(F)(F)F)O)C)CO SPYOYOMYCMZYIV-UHFFFAOYSA-N 0.000 description 1
- LGGPZDRLTDGYSQ-JADSYQMUSA-N 4-[[4-[[(2r,4s)-4-(3-chlorophenyl)-2-oxo-1,3,2$l^{5}-dioxaphosphinan-2-yl]methoxy]-2,6-dimethylphenyl]methyl]-2-propan-2-ylphenol Chemical compound C1=C(O)C(C(C)C)=CC(CC=2C(=CC(OC[P@]3(=O)O[C@@H](CCO3)C=3C=C(Cl)C=CC=3)=CC=2C)C)=C1 LGGPZDRLTDGYSQ-JADSYQMUSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010070817 Bone decalcification Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- YVECGMZCTULTIS-HSUXUTPPSA-N D-galactal Chemical compound OC[C@H]1OC=C[C@@H](O)[C@H]1O YVECGMZCTULTIS-HSUXUTPPSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 241001484259 Lacuna Species 0.000 description 1
- 208000004552 Lacunar Stroke Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100347623 Mus musculus Myrf gene Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical group 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 101000779336 Oryza sativa subsp. japonica Fructose-bisphosphate aldolase 1, cytoplasmic Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010060932 Postoperative adhesion Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 229940121886 Thyroid hormone receptor agonist Drugs 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 101100347624 Xenopus laevis myrf gene Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 101150045969 abcD1 gene Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000005426 adeninyl group Chemical group N1=C(N=C2N=CNC2=C1N)* 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 102000005922 amidase Human genes 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 125000002676 chrysenyl group Chemical group C1(=CC=CC=2C3=CC=C4C=CC=CC4=C3C=CC12)* 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- MQYQOVYIJOLTNX-UHFFFAOYSA-N dichloromethane;n,n-dimethylformamide Chemical compound ClCCl.CN(C)C=O MQYQOVYIJOLTNX-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002828 effect on organs or tissue Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229950011248 eprotirome Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- OWNHEHCHUWTDGH-UHFFFAOYSA-N ethyl 2-[3-bromo-4-(chloromethyl)-5-methylphenoxy]acetate Chemical compound O(CC(=O)OCC)C1=CC(=C(C(C)=C1)CCl)Br OWNHEHCHUWTDGH-UHFFFAOYSA-N 0.000 description 1
- CLKWFLOKQXONHO-UHFFFAOYSA-N ethyl 2-[3-bromo-4-(hydroxymethyl)-5-methylphenoxy]acetate Chemical compound O(CC(=O)OCC)C1=CC(=C(C(=C1)C)CO)Br CLKWFLOKQXONHO-UHFFFAOYSA-N 0.000 description 1
- HORDAKDMOFANRO-UHFFFAOYSA-N ethyl 2-[3-bromo-5-chloro-4-(chloromethyl)phenoxy]acetate Chemical compound C(OC1=CC(=C(C(Cl)=C1)CCl)Br)C(=O)OCC HORDAKDMOFANRO-UHFFFAOYSA-N 0.000 description 1
- KXAUPVSWAHDZPX-UHFFFAOYSA-N ethyl 2-[3-bromo-5-chloro-4-(hydroxymethyl)phenoxy]acetate Chemical compound C(=O)(COC1=CC(=C(C(Cl)=C1)CO)Br)OCC KXAUPVSWAHDZPX-UHFFFAOYSA-N 0.000 description 1
- RNAHBXALBJCLEB-UHFFFAOYSA-N ethyl 2-[3-chloro-4-(chloromethyl)-5-(trifluoromethyl)phenoxy]acetate Chemical compound C(OC1=CC(C(F)(F)F)=C(CCl)C(Cl)=C1)C(=O)OCC RNAHBXALBJCLEB-UHFFFAOYSA-N 0.000 description 1
- PSMZAVMEPDTBPZ-UHFFFAOYSA-N ethyl 2-[3-chloro-4-(chloromethyl)-5-ethylphenoxy]acetate Chemical compound O(CC(=O)OCC)C1=CC(Cl)=C(CCl)C(CC)=C1 PSMZAVMEPDTBPZ-UHFFFAOYSA-N 0.000 description 1
- SOKVARVAYPLIHA-UHFFFAOYSA-N ethyl 2-[3-chloro-4-(hydroxymethyl)-5-(trifluoromethyl)phenoxy]acetate Chemical compound O(CC(=O)OCC)C1=CC(Cl)=C(CO)C(C(F)(F)F)=C1 SOKVARVAYPLIHA-UHFFFAOYSA-N 0.000 description 1
- SFJXSPYDZUCQHE-UHFFFAOYSA-N ethyl 2-[3-chloro-5-ethyl-4-(hydroxymethyl)phenoxy]acetate Chemical compound O(CC(=O)OCC)C1=CC(Cl)=C(CO)C(CC)=C1 SFJXSPYDZUCQHE-UHFFFAOYSA-N 0.000 description 1
- ZPIUIDIWMKPQKB-UHFFFAOYSA-N ethyl 2-[4-(chloromethyl)-3-methyl-5-(trifluoromethyl)phenoxy]acetate Chemical compound C(OC1=CC(=C(C(=C1)C)CCl)C(F)(F)F)C(=O)OCC ZPIUIDIWMKPQKB-UHFFFAOYSA-N 0.000 description 1
- VEVXXYTXYYMCQA-UHFFFAOYSA-N ethyl 2-[4-(hydroxymethyl)-3-methyl-5-(trifluoromethyl)phenoxy]acetate Chemical compound O(CC(=O)OCC)C1=CC(=C(C(C)=C1)CO)C(F)(F)F VEVXXYTXYYMCQA-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002192 heptalenyl group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 150000002443 hydroxylamines Chemical group 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 125000003427 indacenyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000003458 metachromatic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- GIWILNCYEFAOFJ-UHFFFAOYSA-N methyl 2-[3-bromo-4-(chloromethyl)-5-methylphenoxy]acetate Chemical compound C(OC1=CC(=C(C(C)=C1)CCl)Br)C(=O)OC GIWILNCYEFAOFJ-UHFFFAOYSA-N 0.000 description 1
- HQAODICDKHKUCX-UHFFFAOYSA-N methyl 2-[3-bromo-4-(hydroxymethyl)-5-methylphenoxy]acetate Chemical compound O(CC(=O)OC)C1=CC(=C(C(=C1)C)CO)Br HQAODICDKHKUCX-UHFFFAOYSA-N 0.000 description 1
- XOSPIHZBVWRWFG-UHFFFAOYSA-N methyl 2-[3-chloro-4-(chloromethyl)-5-methylphenoxy]acetate Chemical compound C(OC1=CC(=C(CCl)C(Cl)=C1)C)C(=O)OC XOSPIHZBVWRWFG-UHFFFAOYSA-N 0.000 description 1
- ADCVDRSBDDXAQB-UHFFFAOYSA-N methyl 2-[3-chloro-4-(hydroxymethyl)-5-methylphenoxy]acetate Chemical compound O(CC(=O)OC)C1=CC(=C(CO)C(=C1)C)Cl ADCVDRSBDDXAQB-UHFFFAOYSA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- NQFNUSXQFSJQAN-UHFFFAOYSA-N oxolane;thionyl dichloride Chemical compound ClS(Cl)=O.C1CCOC1 NQFNUSXQFSJQAN-UHFFFAOYSA-N 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- JZWFDVDETGFGFC-UHFFFAOYSA-N salacetamide Chemical group CC(=O)NC(=O)C1=CC=CC=C1O JZWFDVDETGFGFC-UHFFFAOYSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000007847 structural defect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000004927 thianaphthalenyl group Chemical group S1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 125000003960 triphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C3=CC=CC=C3C12)* 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/14—Acetic acid esters of monohydroxylic compounds
- C07C69/145—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols
- C07C69/157—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/34—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings containing more than one carboxyl group
- C07C57/36—Phenymalonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
- C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
- C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Abstract
Description
甲状腺ホルモン(TH)は、発達中のオリゴデンドロサイト分化と髄鞘形成において重要なシグナルであり、さらには多発性硬化症(MS)の成人モデルに対し再有髄化を刺激する(Calza et al.,Brain Res Revs 48:339-346,2005)。しかしTHは、慢性甲状腺機能亢進症に関連する心臓毒性と骨脱灰を回避しながら再有髄化を達成可能な治療可能時間域が限られていることから、許容可能な長期療法ではない。一部の甲状腺ホルモンアナログは、甲状腺ホルモン受容体(TR)の分子特徴と生理特徴を活用することでTHに随伴するマイナス面を回避しながら甲状腺ホルモン反応遺伝子を活性化することができる(Malm et al.,Mini Rev Med Chem 7:79-86,2007)。これら受容体は、不均質な組織分布と重複を持つ、2つの主要な形態ではあるが別々の標的遺伝子集団に発現される(Yen,Physiol Rev 81:1097-1142,2001)。TRαは心臓、脳、および骨で豊富であり、一方でTRβは肝臓で豊富である(O’Shea et al.,Nucl Recept Signal 4:e011,2006)。
X1とX2は、ハロ、低級アルキル、低級アルケニル、低級ハロアルキル、低級アルコキシ、低級ハロアルコキシ、シクロアルキル、およびシクロアルキルアルキルであり、
ここで、
X1とX2は同じ分子式を持たず、または
X1とX2には同じ分子式があり、かつX1とX2には同じ結合性あるいは構成がなく、
R1は-NR1aR1bまたは-OR1cであり、
R1aとR1bはそれぞれ独立して、H、-ORa、-NRaRb、低級アルキル、低級アルケニル、低級アルキニル、カルボシクリル、カルボシクリルアルキル、ヘテロシクリル、またはヘテロシクリルアルキルであり、RaとRbはそれぞれ独立して、Hまたは低級アルキルであり、ならびに
R1cは、H、低級アルキル、カルボシクリル、ヘテロシクリル、カルボシクリルアルキル、またはヘテロシクリルアルキルであり、
ここで、R1a、R1b、R1c、Ra、およびRbはそれぞれ独立して、1つ以上のハロ、シアノ、-OR’、-NR’R”、-S(O)2R’、または-S(O)2OR’で随意に置換され、R’とR”はそれぞれ独立して、Hまたは低級アルキルである。
X1とX2は、ハロ、低級アルキル、低級アルケニル、低級ハロアルキル、低級アルコキシ、低級ハロアルコキシ、シクロアルキル、およびシクロアルキルアルキルであり、
ここで、
X1とX2は同じ分子式を持たず、または
X1とX2には同じ分子式があり、およびX1とX2には同じ結合性または構成がなく、ならびに
R1aとR1bはそれぞれ独立して、H、-ORa、-NRaRb、低級アルキル、低級アルケニル、低級アルキニル、カルボシクリル、カルボシクリルアルキル、ヘテロシクリル、またはヘテロシクリルアルキルであり、
ここでRaとRbはそれぞれ独立して、Hまたは低級アルキルであり、ならびに
R1a、R1b、Ra、およびRbはそれぞれ独立して、1つ以上のハロ、シアノ、-OR’、-NR’R”、-S(O)2R’、または-S(O)2OR’で随意に置換され、R’とR”はそれぞれ独立して、Hまたは低級アルキルである。
X1とX2は、ハロ、低級アルキル、低級アルケニル、低級ハロアルキル、低級アルコキシ、低級ハロアルコキシ、シクロアルキル、およびシクロアルキルアルキルであり、
ここで、
X1とX2は同じ分子式を持たず、または
X1とX2には同じ分子式があり、およびX1とX2には同じ結合性または構成がなく、ならびに
R1cはH、低級アルキル、カルボシクリル、ヘテロシクリル、カルボシクリルアルキル、またはヘテロシクリルアルキルであり、ここでR1cは、1つ以上のハロ、シアノ、-OR’、-NR’R”、-S(O)2R’、または-S(O)2OR’で随意に置換され、R’とR”はそれぞれ独立して、Hまたは低級アルキルである。
X1とX2は、ハロ、低級アルキル、低級アルケニル、低級ハロアルキル、低級アルコキシ、低級ハロアルコキシ、シクロアルキル、およびシクロアルキルアルキルであり、
ここで、
X1とX2は同じ分子式を持たず、または
X1とX2には同じ分子式があり、かつX1とX2には同じ結合性あるいは構成がない。
合成が実験部分に記載されていないすべての試薬は、市販されているか、または周知の化合物であるか、または当業者によって既知方法で既知の化合物から形成されてもよい。
以下の略語が実施例では使用されるが、その他の略語は当該技術分野において慣用的な意味を有する:
CH2O:ホルムアルデヒド
Cs2CO3:炭酸セシウム
d:日
DCE:ジクロロエタン
DCM:ジクロロメタン
DMF:ジメチルホルムアミド
DMSO:ジメチルスルホキシド
EDTA:エチレンジアミン四酢酸
ELISA:酵素結合免疫吸着測定法
EtOAc:酢酸エチル
h:時間
HCl:塩酸
HPLC:高速液体クロマトグラフィー
H2SO4:硫酸
K2CO3:炭酸カリウム
l:リットル
LCMS:液体クロマトグラフィー-質量分析法
LiOH:水酸化リチウム
M:モル
MeCN:アセトニトリル
min:分
μl:マイクロリットル
ml:ミリリットル
NaNO2:亜硝酸ナトリウム
NaOH:水酸化ナトリウム
Na2SO4:硫酸ナトリウム
NMP:N-メチル-2-ピロリドン
NMR:核磁気共鳴分光法
PE:石油エーテル
Pd/C:パラジウム炭素
RP:逆相
rt:室温
Rt:保持時間
sat.:飽和
SOCl2:塩化チオニル
THF:テトラヒドロフラン
ZnCl2:塩化亜鉛
3-クロロ-4-(ヒドロキシメチル)-5-メチル-フェノール(中間体A)の合成
メチル2-(3-クロロ-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-メチルフェノキシ)アセテート(化合物1)の合成
2-(3-クロロ-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-メチルフェノキシ)酢酸(化合物2)の合成
2-(3-クロロ-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-メチルフェノキシ)-N-メチルアセトアミド(化合物3)の合成
メチル2-(3-ブロモ-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-メチルフェノキシ)アセテート(化合物4)の合成
2-(3-ブロモ-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-メチルフェノキシ)酢酸(化合物5)の合成
2-(3-ブロモ-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-メチルフェノキシ)-N-メチルアセトアミド(化合物6)の合成
エチル2-(3-クロロ-5-エチル-4-(4-ヒドロキシ-3-イソプロピルベンジル)フェノキシ)アセテート(化合物7)の合成
2-(3-クロロ-5-エチル-4-(4-ヒドロキシ-3-イソプロピルベンジル)フェノキシ)酢酸(化合物8)の合成
2-(3-クロロ-5-エチル-4-(4-ヒドロキシ-3-イソプロピルベンジル)フェノキシ)-N,N-ジメチルアセトアミド(化合物9)の合成
エチル2-(4-(4-ヒドロキシ-3-イソプロピルベンジル)-3-メチル-5-(トリフルオロメチル)フェノキシ)アセテート(化合物10)の合成
2-(4-(4-ヒドロキシ-3-イソプロピルベンジル)-3-メチル-5-(トリフルオロメチル)フェノキシ)酢酸(化合物11)の合成
エチル2-(3-ブロモ-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-メチルフェノキシ)アセテート(化合物12)の合成
エチル2-(4-(4-ヒドロキシ-3-イソプロピルベンジル)-3-メチル-5-ビニルフェノキシ)アセテート(化合物13)の合成
2-(4-(4-ヒドロキシ-3-イソプロピルベンジル)-3-メチル-5-ビニルフェノキシ)酢酸(化合物14)の合成
エチル2-(3-エチル-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-メチルフェノキシ)アセテート(化合物15)の合成
2-(3-エチル-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-メチルフェノキシ)酢酸(化合物16)の合成
エチル2-(3-クロロ-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-(トリフルオロメチル)フェノキシ)アセテート(化合物17)の合成
2-(3-クロロ-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-(トリフルオロメチル)フェノキシ)酢酸(化合物)の合成
エチル2-(4-(4-ヒドロキシ-3-イソプロピルベンジル)-3-メチル-5-(プロプ-1-エン-2-イル)フェノキシ)アセテート(化合物19)の合成
2-(4-(4-ヒドロキシ-3-イソプロピルベンジル)-3-メチル-5-(プロプ-1-エン-2-イル)フェノキシ)酢酸(化合物20)の合成
2-(4-(4-ヒドロキシ-3-イソプロピルベンジル)-3-イソプロピル-5-メチルフェノキシ)酢酸(化合物21)の合成
(E)-エチル2-(4-(4-ヒドロキシ-3-イソプロピルベンジル)-3-メチル-5-(プロプ-1-エニル)フェノキシ)アセテート(化合物22)の合成
(E)-2-(4-(4-ヒドロキシ-3-イソプロピルベンジル)-3-メチル-5-(プロプ-1-エニル)フェノキシ)酢酸(化合物23)の合成
エチル2-(4-(4-ヒドロキシ-3-イソプロピルベンジル)-3-メチル-5-プロピルフェノキシ)アセテート(化合物24)の合成
2-(4-(4-ヒドロキシ-3-イソプロピルベンジル)-3-メチル-5-プロピルフェノキシ)酢酸(化合物25)の合成
エチル2-(3-シクロプロピル-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-メチルフェノキシ)アセテート(化合物26)の合成
2-(3-シクロプロピル-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-メチルフェノキシ)酢酸(化合物27)の合成
エチル2-(3-ブロモ-5-クロロ-4-(4-ヒドロキシ-3-イソプロピルベンジル)フェノキシ)アセテート(化合物28)の合成
エチル2-(3-クロロ-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-(プロプ-1-エン-2-イル)フェノキシ)アセテート(化合物29)の合成
2-(3-クロロ-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-(プロプ-1-エン-2-イル)フェノキシ)酢酸(化合物30)の合成
2-(3-クロロ-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-イソプロピルフェノキシ)酢酸(化合物31)の合成
2-(3-クロロ-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-(プロプ-1-エン-2-イル)フェノキシ)塩化アセチル(化合物32)の合成
2-(3-クロロ-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-(プロプ-1-エン-2-イル)フェノキシ)-N-メチルアセトアミド(化合物33)の合成
2-(3-クロロ-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-(プロプ-1-エン-2-イル)フェノキシ)-N,N-ジメチルアセトアミド(化合物34)の合成
2-(3-クロロ-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-イソプロピルフェノキシ)-N-メチルアセトアミド(化合物35)の合成
2-(3-クロロ-4-(4-ヒドロキシ-3-イソプロピルベンジル)-5-イソプロピルフェノキシ)-N,N-ジメチルアセトアミド(化合物36)の合成
甲状腺ホルモンレポーター遺伝子アッセイ
化合物2および5は、TRレポーター遺伝子アッセイを使用して、甲状腺ホルモン受容体(TR)活性について試験された。本アッセイに使用したレポーター細胞は、ネイティブなN末端DNA結合ドメイン(DBD)が酵母Gal4 DBDのそれと取り替えられた、TR-受容体ハイブリッド(TRαまたはTRβ)を発現している。レポーター遺伝子であるホタルルシフェラーゼは、Gal4上流活性化配列(UAS)と機能的に連結している。両方の細胞株はヒト胚性腎臓(HEK293)に由来する。
効力コード: + EC50>1,000nM
++ 100nM<EC50≦1,000nM
+++ 10nM<EC50≦100nM
++++ EC50≦10nM
選択性コード:+ T3-SI≦3X
++ 3X<T3-SI≦30X
+++ T3-SI>30X
インビボ活性
動物試験
本発明の化合物は、以下のプロトコルに従って、インビボモデルで甲状腺ホルモン受容体アゴニスト活性について試験され得る。
オスのC57Bl/6マウスを用いた組織濃度試験では、試験化合物を0.05mg/mLの濃度でNMP/ソルトール/PBS溶液として製剤化し、SC注射または経口投与により、標的用量0.100mg/kgを2mL/kgで投与した。投与後0.5、2、8、および24時間(AUC測定用)または1時間(単一のタイムポイント)に血漿、脳、肝臓、肺、腎臓、心臓、およびその他の選択した組織試料を、各タイムポイントにつき3匹の動物で採取する。試験化合物の組織ホモジネートと血漿濃度は、LC MS/MSを用いて、定量下限値を0.0200ng/mLまたは0.100ng/gとして、判定される。薬物動態パラメータは、WinNonlinを使用して、非コンパートメント方法によって決定される。
成熟したオスのスプラーグドーリーラットまたはC57BL/6マウスに、最大で3つの用量レベル(例えば、上記のコレステロール低下試験で得られたED50値の1倍、3倍、および10倍)の試験化合物を経口投与する。あらかじめ決められた時間、つまり、試験化合物の投与の4時間後、8時間後、24時間後に、げっ歯類を麻酔し、採血して血漿試料を採取し、薬物濃度を測定する。限定されないが、肝臓、脳、腎臓、心臓、肺、骨格筋、下垂体、および精巣などの複数の臓器の試料を採取し、RNA解析のために処理する。試料は、RNAを単離した後にRNA-Seqで解析されるか、または、Quantigene(商標)などのRNA単離を必要としない適切なプラットフォームを用いて標的遺伝子解析によって分析される。複数の遺伝子を用いて、各組織におけるT3媒介性の遺伝子シグネチャーを表現する。組織ごとに異なる遺伝子を使用し、すべての遺伝子を複数のハウスキーピング遺伝子に正規化して全体的なRNA品質のばらつきを考慮する。
式IIのアミドは、FAAHなどのアミダーゼの作用により、式IVの活性アゴニスト酸に変換され得る。同様に、式IIIのエステルは、様々なエステラーゼの作用により、式IVの活性なアゴニスト酸に変換され得る。このインビボの変換は、以下に記載されるように、試験化合物のレベルを測定する薬物動態試験によって実証することができる。
Claims (91)
- 式(I)の構造を有する化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩であって、
X1とX2は、ハロ、低級アルキル、低級アルケニル、低級ハロアルキル、低級アルコキシ、低級ハロアルコキシ、シクロアルキル、およびシクロアルキルアルキルであり、
ここで、
X1とX2は同じ分子式を持たず、または
X1とX2には同じ分子式があり、かつX1とX2には同じ結合性あるいは構成がなく、
R1は-NR1aR1bまたは-OR1cであり、
R1aとR1bはそれぞれ独立して、H、-ORa、-NRaRb、低級アルキル、低級アルケニル、低級アルキニル、カルボシクリル、カルボシクリルアルキル、ヘテロシクリル、またはヘテロシクリルアルキルであり、RaとRbはそれぞれ独立して、Hまたは低級アルキルであり、ならびに
R1cは、H、低級アルキル、カルボシクリル、ヘテロシクリル、カルボシクリルアルキル、またはヘテロシクリルアルキルであり、
ここで、R1a、R1b、R1c、Ra、およびRbはそれぞれ独立して、1つ以上のハロ、シアノ、-OR’、-NR’R”、-S(O)2R’、または-S(O)2OR’で随意に置換され、R’とR”はそれぞれ独立して、Hまたは低級アルキルである、化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。 - 式(I)の構造を有する化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩であって、
X1は、ハロ、低級アルキル、低級ハロアルキル、低級アルケニル、またはシクロアルキルであり、
X2はハロまたは低級アルキルであり、
ここで、
X1とX2は同じ分子式を持たず、または
X1とX2には同じ分子式があり、かつX1とX2には同じ結合性あるいは構成がなく、
R1は-NR1aR1bまたは-OR1cであり、
R1aとR1bはそれぞれ独立して、H、-ORa、-NRaRb、低級アルキル、低級アルケニル、低級アルキニル、カルボシクリル、カルボシクリルアルキル、ヘテロシクリル、またはヘテロシクリルアルキルであり、RaとRbはそれぞれ独立して、Hまたは低級アルキルであり、ならびに
R1cは、H、低級アルキル、カルボシクリル、ヘテロシクリル、カルボシクリルアルキル、またはヘテロシクリルアルキルであり、
ここで、R1a、R1b、R1c、Ra、およびRbはそれぞれ独立して、1つ以上のハロ、シアノ、-OR’、-NR’R”、-S(O)2R’、または-S(O)2OR’で随意に置換され、R’とR”はそれぞれ独立して、Hまたは低級アルキルである、化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。 - R1aがHまたは低級アルキルである、請求項1から3のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- R1aがHである、請求項1から3のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- R1aが低級アルキルである、請求項1から3のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- R1aがメチルである、請求項1から3、または6のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- R1bがHまたは低級アルキルである、請求項1から7のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- R1bがHである、請求項1から7のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- R1bが低級アルキルである、請求項1から7のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- R1bがメチルである、請求項1から7、または10のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- R1cが低級アルキルである、請求項1、2、または12のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- R1cがメチルまたはエチルである、請求項1、2、12、または13のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- R1cがメチルである、請求項1、2、12、または13のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- R1cがエチルである、請求項1、2、12、または13のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X1が低級アルキルである、請求項1から17のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X1がメチル、エチル、プロピル、またはイソプロピルである、請求項1から18のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X1がメチルである、請求項1から18のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X1がエチルである、請求項1から18のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X1がプロピルである、請求項1から18のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X1がイソプロピルである、請求項1から18のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X1が低級アルキレンである、請求項1から17のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X1がエテニル、プロペニル、またはイソプロペニルである、請求項1から17、または24のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X1がエテニルである、請求項1から17、または24のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X1がプロペニルである、請求項1から17、または24のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X1がイソプロペニルである、請求項1から17、または24のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X1がシクロアルキルである、請求項1から17のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X1がシクロプロピルである、請求項1から17、または30のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X1が低級ハロアルキルである、請求項1から17のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X1がトリフルオロメチルである、請求項1から17、または32のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X1がハロである、請求項1から17のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X1がBrである、請求項1から17、または34のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X2がハロである、請求項1から35のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X2がClまたはBrである、請求項1から36のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X2がClである、請求項1から36のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X2がBrである、請求項1から36のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X2が低級アルキルである、請求項1から35のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- X2がメチルである、請求項1から35、または40のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩。
- 請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な異性体、ラセミ体、水和物、溶媒和物、同位体、あるいは塩と、薬学的に許容可能な賦形剤とを含む医薬組成物。
- 神経変性疾患の被験体を処置する方法であって、請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物を薬学的に有効な量で前記被験体に投与する工程を含む、方法。
- 前記神経変性疾患が脱髄疾患である、請求項44に記載の方法。
- 前記神経変性疾患が慢性脱髄疾患である、請求項44または45に記載の方法。
- 前記神経変性疾患が、X結合遺伝性疾患、白質萎縮症、痴呆症、タウオパチー、または虚血性脳卒中である、請求項44または45に記載の方法。
- 前記神経変性疾患が、多発性硬化症、MCT8欠乏症、X結合副腎白質ジストロフィー(ALD)、筋萎縮性側索硬化症(ALS)、アルツハイマー病、前頭側頭型認知症、または小空洞性卒中である、請求項47に記載の方法。
- 前記神経変性疾患が、成人性レフサム病、アレキサンダー病、アルツハイマー病、バロー同心円性硬化症、カナバン病、橋中心髄鞘崩壊症、脳性麻痺、脳腱黄色腫症、慢性炎症性脱髄性多発ニューロパチー、デビック症候群、びまん性骨髄破砕性硬化症、特発性炎症性脱髄疾患、幼児性レフサム病、クラッベ病、レーベル遺伝性視神経症、マールブルク多発性硬化症、マルキアファーヴァ-ビニャーミ病、異染性白質萎縮症、多巣性運動ニューロパチー、異常タンパク性脱髄性多発神経障害、ペリツェウス-メルツバッハー病、腓骨筋萎縮、進行性多病巣性白質脳症、横断脊髄炎、熱帯性痙性不全対麻痺、ファンデルクナップ病、X結合副腎白質ジストロフィー、またはツェルヴェーガー症候群である、請求項44または45に記載の方法。
- 神経発達障害の被験体を処置する方法であって、請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物を薬学的に有効な量で前記被験体に投与する工程を含む、方法。
- 前記神経発達障害には髄鞘形成に対する副作用がある、請求項50に記載の方法。
- 前記神経発達障害がトリソミーである、請求項50に記載の方法。
- 前記神経発達障害がダウン症候群である、請求項50に記載の方法。
- TGF-βの過剰発現に関連する健康状態の被験体を処置する方法であって、請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物を薬学的に有効な量で前記被験体に投与する工程を含む、方法。
- 前記TGF-βの過剰発現に関連する健康状態が線維性疾患である、請求項54に記載の方法。
- 前記TGF-βの過剰発現に関連する健康状態が、非アルコール性脂肪性肝炎(NASH)、特発性肺線維症(IPF)、全身性強皮症、またはアルポート症候群である、請求項54または55に記載の方法。
- 成人性レフサム病、幼児性レフサム病、アレキサンダー病、アルツハイマー病、バロー同心円性硬化症、カナバン病、橋中心髄鞘崩壊症(CPM)、脳性麻痺、脳腱黄色腫症、慢性炎症性脱髄性多発ニューロパチー(CIDP)、デビック症候群、びまん性骨髄破砕性硬化症、脳脊髄炎、特発性炎症性脱髄疾患(IIDD)、クラッベ病、レーベル遺伝性視神経症、白質萎縮症、マールブルク多発性硬化症、マルキアファーヴァ-ビニャーミ病、異染性白質萎縮症(MLD)、多巣性運動ニューロパチー(MMN)、多発性硬化症(MS)、異常タンパク性脱髄性多発神経障害、ペリツェウス-メルツバッハー病(PMD)、進行性多病巣性白質脳症(PML)、熱帯性痙性不全対麻痺(TSP)、X結合副腎白質ジストロフィー(X-ALD、ALO、あるいはX結合ALO)、ツェルヴェーガー症候群、MCT8欠乏症、筋萎縮性側索硬化症(ALS)、前頭側頭型認知症、小空洞性卒中、原発性年齢関連タウオパチー(PART)、ピック病、17番染色体に連鎖しパーキンソニズムを伴う前頭側頭型認知症(FTDP-17)、副腎脊髄神経障害(AMN)、大脳型副腎白質ジストロフィー(cALD)、非アルコール性脂肪性肝炎(NASH)、特発性肺線維症(IPF)、全身性強皮症、またはアルポート症候群の被験体を処置する方法であって、請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物を薬学的に有効な量で前記被験体に投与する工程を含む、方法。
- NASH、NAFLD、高脂血症を伴うNAFLD、アルコール性肝疾患/アルコール性脂肪性肝炎、ウイルス感染(HBV、HCV)関連性肝線維症、胆汁うっ滞性疾患(原発性胆汁性胆管炎、原発性硬化性胆管炎)関連性線維症、(家族性)高コレステロール血症、脂質異常症、遺伝性脂質障害、肝硬変、アルコール誘発性線維症、ヘモクロマトーシス、糖原病、α-1-アンチトリプシン欠乏症、自己免疫性肝炎、ウィルソン病、クリグラー-ナジャー症候群、リゾリーマル酸リパーゼ欠乏症、膵嚢胞性線維症における肝疾患の被験体を処置する方法であって、請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物を薬学的に有効な量で前記被験体に投与する工程を含む、方法。
- アルポート症候群、糖尿病腎症、FSGS、IgA腎症関連性線維症、慢性腎臓病(CKD)、ポストAKI、HIV関連性CKD、化学療法誘発性CKD、腎毒性薬剤関連性CKD、腎形成性全身性線維症、尿細管間質性線維症、糸球体硬化症、または多発性嚢胞腎(PKD)の被験体を処置する方法であって、請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物を薬学的に有効な量で前記被験体に投与する工程を含む、方法。
- IPF、ILD、肺線維症、関節リウマチ、強皮症、あるいはシェーグレン症候群のような自己免疫疾患関連性肺線維症、喘息関連性肺線維症、COPD、アスベストあるいはシリカ誘発性PF、珪肺症、呼吸器細気管支炎、特発性間質性肺炎(IIP)、特発性非特異的間質性肺炎、呼吸器細気管支炎間質性肺疾患、剥離性間質性肺炎、急性間質性肺炎、稀なIIP:特発性リンパ球様間質性肺炎、特発性胸膜肺実質線維弾性症、分類不能型特発性間質性肺炎、過敏性肺炎、放射線誘発性肺損傷、進行性塊状線維症、塵肺症、気管支拡張症、綿肺症、慢性呼吸疾患、慢性閉塞性肺疾患(COPD)、肺気腫、肺高血圧症(PAH)、または膵嚢胞性線維症の被験体を処置する方法であって、請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物を薬学的に有効な量で前記被験体に投与する工程を含む、方法。
- 強皮症/全身性硬化症、移植片対宿主病、過形成性瘢痕、ケロイド、腎形成性全身性線維症、晩発性皮膚ポルフィリン症、拘束性皮膚障害、デュピュイトラン拘縮、皮膚線維症、腎形成性全身性線維症/腎性線維化性皮膚症、混合結合組織病、硬化性粘液水腫、好酸球性筋膜炎、化学製品あるいは物理的因子への曝露により生じる線維症、GvHD誘発性線維症、成年性浮腫性硬化症、脂肪皮膚硬化症、または早老性障害(早老症、先端老変症、ヴェルナー症候群)の被験体を処置する方法であって、請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物を薬学的に有効な量で前記被験体に投与する工程を含む、方法。
- 心房性線維症、心内膜心筋線維症、心臓性線維症、アテローム動脈硬化症、再狭窄症、または関節線維症の被験体を処置する方法であって、請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物を薬学的に有効な量で前記被験体に投与する工程を含む、方法。
- 縦隔線維症、骨髄線維症、真性赤血球増加症後骨髄線維症、または後本態性血小板血症の被験体を処置する方法であって、請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物を薬学的に有効な量で前記被験体に投与する工程を含む、方法。
- クローン病、後腹膜線維症、腸線維症、炎症性腸疾患における線維症、潰瘍性大腸炎、膵嚢胞性線維症原因のGI線維症、または膵臓炎原因の膵線維症の被験体を処置する方法であって、請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物を薬学的に有効な量で前記被験体に投与する工程を含む、方法。
- 子宮内膜線維症、子宮線維症、またはペイロニー病の被験体を処置する方法であって、請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物を薬学的に有効な量で前記被験体に投与する工程を含む、方法。
- 黄斑変性、糖尿病性網膜症、網膜血管結合組織疾患、または硝子体網膜症の被験体を処置する方法であって、請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物を薬学的に有効な量で前記被験体に投与する工程を含む、方法。
- 外傷に関連する瘢痕の被験体を処置する方法であって、請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物を薬学的に有効な量で前記被験体に投与する工程を含む、方法。
- 前記外傷に関連する瘢痕は、外科合併症、化学療法、薬剤性線維症、または放射線誘導性線維症に関連する、請求項67に記載の方法。
- 神経変性疾患の処置に使用するための請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- 前記神経変性疾患が脱髄疾患である、請求項69に記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- 前記神経変性疾患が慢性脱髄疾患である、請求項69または70に記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- 前記神経変性疾患が、X結合遺伝性疾患、白質萎縮症、痴呆症、タウオパチー、または虚血性脳卒中である、請求項69または70に記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- 前記神経変性疾患が、多発性硬化症、MCT8欠乏症、X結合副腎白質ジストロフィー(ALD)、筋萎縮性側索硬化症(ALS)、アルツハイマー病、前頭側頭型認知症、または小空洞性卒中である、請求項72に記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- 前記神経変性疾患が、成人性レフサム病、アレキサンダー病、アルツハイマー病、バロー同心円性硬化症、カナバン病、橋中心髄鞘崩壊症、脳性麻痺、脳腱黄色腫症、慢性炎症性脱髄性多発ニューロパチー、デビック症候群、びまん性骨髄破砕性硬化症、特発性炎症性脱髄疾患、幼児性レフサム病、クラッベ病、レーベル遺伝性視神経症、マールブルク多発性硬化症、マルキアファーヴァ-ビニャーミ病、異染性白質萎縮症、多巣性運動ニューロパチー、異常タンパク性脱髄性多発神経障害、ペリツェウス-メルツバッハー病、腓骨筋萎縮、進行性多病巣性白質脳症、横断脊髄炎、熱帯性痙性不全対麻痺、ファンデルクナップ病、X結合副腎白質ジストロフィー、またはツェルヴェーガー症候群である、請求項69または70に記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- 神経発達障害の処置に使用するための請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- 前記神経発達障害がダウン症候群である、請求項75に記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- TGF-βの過剰発現に関連する健康状態の処置に使用するための請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- 前記TGF-βの過剰発現に関連する健康状態が線維性疾患である、請求項77に記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- TGF-βの過剰発現に関連する健康状態が、非アルコール性脂肪性肝炎(NASH)、特発性肺線維症(IPF)、全身性強皮症、またはアルポート症候群である、請求項77または78に記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- 成人性レフサム病、幼児性レフサム病、アレキサンダー病、アルツハイマー病、バロー同心円性硬化症、カナバン病、橋中心髄鞘崩壊症(CPM)、脳性麻痺、脳腱黄色腫症、慢性炎症性脱髄性多発ニューロパチー(CIDP)、デビック症候群、びまん性骨髄破砕性硬化症、脳脊髄炎、特発性炎症性脱髄疾患(IIDD)、クラッベ病、レーベル遺伝性視神経症、白質萎縮症、マールブルク多発性硬化症、マルキアファーヴァ-ビニャーミ病、異染性白質萎縮症(MLD)、多巣性運動ニューロパチー(MMN)、多発性硬化症(MS)、異常タンパク性脱髄性多発神経障害、ペリツェウス-メルツバッハー病(PMD)、進行性多病巣性白質脳症(PML)、熱帯性痙性不全対麻痺(TSP)、X結合副腎白質ジストロフィー(X-ALD、ALO、あるいはX結合ALO)、ツェルヴェーガー症候群、MCT8欠乏症、筋萎縮性側索硬化症(ALS)、前頭側頭型認知症、小空洞性卒中、原発性年齢関連タウオパチー(PART)、ピック病、17番染色体に連鎖しパーキンソニズムを伴う前頭側頭型認知症(FTDP-17)、副腎脊髄神経障害(AMN)、大脳型副腎白質ジストロフィー(cALD)、非アルコール性脂肪性肝炎(NASH)、特発性肺線維症(IPF)、全身性強皮症、またはアルポート症候群の処置に使用するための請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- NASH、NAFLD、高脂血症を伴うNAFLD、アルコール性肝疾患/アルコール性脂肪性肝炎、ウイルス感染(HBV、HCV)関連性肝線維症、胆汁うっ滞性疾患(原発性胆汁性胆管炎、原発性硬化性胆管炎)関連性線維症、(家族性)高コレステロール血症、脂質異常症、遺伝性脂質障害、肝硬変、アルコール誘発性線維症、ヘモクロマトーシス、糖原病、α-1-アンチトリプシン欠乏症、自己免疫性肝炎、ウィルソン病、クリグラー-ナジャー症候群、リゾリーマル酸リパーゼ欠乏症、膵嚢胞性線維症における肝疾患の処置に使用するための請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- アルポート症候群、糖尿病腎症、FSGS、IgA腎症関連性線維症、慢性腎臓病(CKD)、ポストAKI、HIV関連性CKD、化学療法誘発性CKD、腎毒性薬剤関連性CKD、腎形成性全身性線維症、尿細管間質性線維症、糸球体硬化症、または多発性嚢胞腎(PKD)の処置に使用するための請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- IPF、ILD、肺線維症、関節リウマチ、強皮症、あるいはシェーグレン症候群のような自己免疫疾患関連性肺線維症、喘息関連性肺線維症、COPD、アスベストあるいはシリカ誘発性PF、珪肺症、呼吸器細気管支炎、特発性間質性肺炎(IIP)、特発性非特異的間質性肺炎、呼吸器細気管支炎間質性肺疾患、剥離性間質性肺炎、急性間質性肺炎、稀なIIP:特発性リンパ球様間質性肺炎、特発性胸膜肺実質線維弾性症、分類不能型特発性間質性肺炎、過敏性肺炎、放射線誘発性肺損傷、進行性塊状線維症、塵肺症、気管支拡張症、綿肺症、慢性呼吸疾患、慢性閉塞性肺疾患(COPD)、肺気腫、肺高血圧症(PAH)、または膵嚢胞性線維症の処置に使用するための請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- 強皮症/全身性硬化症、移植片対宿主病、過形成性瘢痕、ケロイド、腎形成性全身性線維症、晩発性皮膚ポルフィリン症、拘束性皮膚障害、デュピュイトラン拘縮、皮膚線維症、腎形成性全身性線維症/腎性線維化性皮膚症、混合結合組織病、硬化性粘液水腫、好酸球性筋膜炎、化学製品あるいは物理的因子への曝露により生じる線維症、GvHD誘発性線維症、成年性浮腫性硬化症、脂肪皮膚硬化症、または早老性障害(早老症、先端老変症、ヴェルナー症候群)の処置に使用するための請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- 心房性線維症、心内膜心筋線維症、心臓性線維症、アテローム動脈硬化症、再狭窄症、または関節線維症の処置に使用するための請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- 縦隔線維症、骨髄線維症、真性赤血球増加症後骨髄線維症、または後本態性血小板血症の処置に使用するための請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- クローン病、後腹膜線維症、腸線維症、炎症性腸疾患における線維症、潰瘍性大腸炎、膵嚢胞性線維症原因のGI線維症、または膵臓炎原因の膵線維症の処置に使用するための請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- 子宮内膜線維症、子宮線維症、またはペイロニー病の処置に使用するための請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- 黄斑変性、糖尿病性網膜症、網膜血管結合組織疾患、または硝子体網膜症の処置に使用するための請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- 外傷に関連する瘢痕の処置に使用するための請求項1から42のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
- 前記外傷に関連する瘢痕は、外科合併症、化学療法、薬剤性線維症、または放射線誘導性線維症に関連する、請求項90に記載の化合物、またはその薬学的に許容可能な塩あるいは組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2018/120634 | 2018-12-12 | ||
PCT/CN2018/120634 WO2020118564A1 (en) | 2018-12-12 | 2018-12-12 | Novel thyromimetics |
US201962907455P | 2019-09-27 | 2019-09-27 | |
US62/907,455 | 2019-09-27 | ||
PCT/US2019/066066 WO2020123861A1 (en) | 2018-12-12 | 2019-12-12 | Novel thyromimetics |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022513449A true JP2022513449A (ja) | 2022-02-08 |
JPWO2020123861A5 JPWO2020123861A5 (ja) | 2022-12-13 |
Family
ID=69160374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021533331A Pending JP2022513449A (ja) | 2018-12-12 | 2019-12-12 | 新規な甲状腺模倣物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11827596B2 (ja) |
EP (1) | EP3894383A1 (ja) |
JP (1) | JP2022513449A (ja) |
CN (1) | CN113423684A (ja) |
AU (1) | AU2019397067A1 (ja) |
CA (1) | CA3122996A1 (ja) |
WO (1) | WO2020123861A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11827596B2 (en) | 2018-12-12 | 2023-11-28 | Autobahn Therapeutics, Inc. | Thyromimetics |
WO2020180624A1 (en) | 2019-03-01 | 2020-09-10 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
US20230348364A1 (en) * | 2020-06-03 | 2023-11-02 | Autobahn Therapeutics, Inc. | Isotopic thyromimetic compounds |
CN112759515B (zh) * | 2020-12-28 | 2023-06-13 | 广东药科大学 | 一种新型FFA1和PPARα/γ/δ四重激动剂、其制备方法及其作为药物的用途 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4723027A (en) | 1982-11-22 | 1988-02-02 | E. I. Du Pont De Nemours And Company | Preparation of optically active alpha-hydroxynitriles |
JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
CA1256638A (en) | 1984-07-06 | 1989-06-27 | Motoaki Tanaka | Polymer and its production |
JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4741897A (en) | 1986-07-08 | 1988-05-03 | Baxter Travenol | Thyroxine analogs and reagents for thyroid hormone assays |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
DE10199033I2 (de) | 1992-04-22 | 2003-01-09 | Ligand Parmaceuticals Inc | Retinoid-x Rezeptor selektive Verbindungen |
DE4320444A1 (de) | 1993-06-21 | 1994-12-22 | Agfa Gevaert Ag | Farbfotografisches Aufzeichnungsmaterial |
WO1997021993A2 (en) | 1995-12-13 | 1997-06-19 | The Regents Of The University Of California | Nuclear receptor ligands and ligand binding domains |
JP3345428B2 (ja) | 1996-08-20 | 2002-11-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 合成甲状腺ホルマン組成物を使用した眼の処置 |
US5883294A (en) | 1997-06-18 | 1999-03-16 | The Regeants Of The University Of California | Selective thyroid hormone analogs |
GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
WO2000000468A1 (en) | 1998-06-30 | 2000-01-06 | The Regents Of The University Of California | Thyroid hormone analogues and methods for their preparation |
GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
AU3711700A (en) | 1999-06-01 | 2000-12-18 | University Of Texas Southwestern Medical Center, The | Biaryl compounds |
US6436990B1 (en) | 1999-10-27 | 2002-08-20 | Nobex Corporation | 6-methoxy-2-naphthylacetic acid prodrugs |
BR0108134A (pt) * | 2000-02-17 | 2003-09-30 | Bristol Myers Squibb Co | Ligantes derivados de anilina para o receptor tiróide |
DE10024939A1 (de) * | 2000-05-19 | 2001-11-29 | Bayer Ag | Neue Diphenylmethanderivate für Arzneimittel |
US6429223B1 (en) | 2000-06-23 | 2002-08-06 | Medinox, Inc. | Modified forms of pharmacologically active agents and uses therefor |
WO2002044166A1 (en) | 2000-11-02 | 2002-06-06 | Astrazeneca Ab | Substituted quinolines as antitumor agents |
US6777442B2 (en) | 2001-03-12 | 2004-08-17 | Bayer Aktiengesellschaft | Diphenyl derivatives |
WO2002081426A1 (en) | 2001-04-05 | 2002-10-17 | Smithkline Beecham Corporation | Peptide deformylase inhibitors |
US7560433B2 (en) | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
AU2003220558A1 (en) | 2002-03-27 | 2004-06-03 | Smithkline Beecham Corporation | Amide compounds and methods of using the same |
US7302347B2 (en) | 2002-12-10 | 2007-11-27 | The Regents Of The University Of California | Method for creating specific, high affinity nuclear receptor pharmaceuticals |
US7321065B2 (en) | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
US8071134B2 (en) | 2003-09-15 | 2011-12-06 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
AU2004293013B2 (en) | 2003-11-19 | 2011-04-28 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
WO2006012015A2 (en) | 2004-06-29 | 2006-02-02 | Oregon Health And Science University | Methods and compositions for nerve regeneration |
CA2583410A1 (en) | 2004-09-15 | 2006-03-23 | Albany College Of Pharmacy | Thyroid hormone analogs for promoting angiogenesis |
MX2007014493A (es) | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Tiromimeticos novedosos que contienen fosforo. |
CN101180097A (zh) | 2005-05-26 | 2008-05-14 | 症变治疗公司 | 新型含次膦酸的拟甲状腺素药 |
EP1890768A2 (en) | 2005-05-26 | 2008-02-27 | Metabasis Therapeutics, Inc. | Novel phosphinic acid-containing thyromimetics |
JP2008542301A (ja) | 2005-05-26 | 2008-11-27 | メタバシス・セラピューティクス・インコーポレイテッド | 脂肪性肝疾患の処置のための甲状腺ホルモン様薬剤 |
GB0606212D0 (en) | 2006-03-28 | 2006-05-10 | Karobio Ab | Pharmaceutical compositions |
GB0608724D0 (en) | 2006-05-03 | 2006-06-14 | Karobio Ab | Novel Pharmaceutical Compositions |
CA2666934A1 (en) | 2006-10-20 | 2008-04-24 | Biogen Idec Ma Inc. | Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor |
CA2704279C (en) | 2006-11-03 | 2014-09-30 | University Of Saskatchewan | Method of treating demyelination diseases |
JP5324463B2 (ja) | 2006-12-10 | 2013-10-23 | チョンシー ユー | β−ラクタム抗生物質の経皮送達システム |
US8008285B2 (en) | 2007-03-09 | 2011-08-30 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia |
FI20075245A0 (fi) | 2007-04-11 | 2007-04-11 | Markku Ahotupa | Menetelmä oksidatiivisen metabolian arvioimiseksi |
EP2187882B1 (en) | 2007-07-11 | 2013-01-09 | MediciNova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
WO2009097995A1 (de) | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2278999A4 (en) | 2008-04-21 | 2015-04-22 | Otonomy Inc | EARLY TREATMENT FORMULATIONS FOR THE TREATMENT OF EARLY DISEASES AND DRESSES |
US8475804B2 (en) | 2009-02-20 | 2013-07-02 | U.S. Army Medical Research And Material Command | Compositions and methods for treatment of filovirus-mediated diseases |
WO2011041686A1 (en) | 2009-10-01 | 2011-04-07 | Mount Sinai School Of Medicine Of New York University | Human type 1 taste receptor subunit 3 modulators and methods of using same |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
JP5847533B2 (ja) | 2010-10-19 | 2016-01-27 | 田辺三菱製薬株式会社 | 新規甲状腺ホルモンβ受容体作動薬 |
US20140288077A1 (en) | 2011-07-05 | 2014-09-25 | St. Jude Children's Research Hospital | Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity |
EP2766018A4 (en) | 2011-10-13 | 2015-02-25 | Univ Case Western Reserve | RXR AGONIST COMPOUNDS AND ASSOCIATED METHODS |
WO2014078892A1 (en) | 2012-11-21 | 2014-05-30 | Indyk Daniel | A device and a test assembly for testing the integrity of a low voltage electrical network |
JP2016517883A (ja) | 2013-05-03 | 2016-06-20 | オレゴン ヘルス アンド サイエンス ユニバーシティー | X連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 |
CN105764884B (zh) | 2013-07-22 | 2019-01-18 | 新陈代谢解决方案开发公司 | 用于治疗代谢疾病的ppar-节制性化合物 |
US10258613B2 (en) | 2014-02-05 | 2019-04-16 | The Board Of Regents Of The University Of Oklahoma | Compositions for treating retinal degeneration and methods of production and use thereof |
WO2015188015A1 (en) | 2014-06-04 | 2015-12-10 | Haro Pharmaceutical Inc. | 18-20 member bi-polycyclic compounds |
WO2016057322A1 (en) | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
CN107848940A (zh) | 2015-02-20 | 2018-03-27 | 俄勒冈健康科学大学 | Sobeirome衍生物 |
WO2017015360A1 (en) | 2015-07-20 | 2017-01-26 | Oregon Health & Science University | Quinolone-3-diarylethers |
HUE056357T2 (hu) * | 2016-05-18 | 2022-02-28 | Univ Oregon Health & Science | Szobetirom származékok |
RU2759913C2 (ru) | 2016-08-12 | 2021-11-18 | Орегон Хэлт Энд Сайенс Юниверсити | Амидные соединения, содержащие их фармацевтические композиции и способы их применения |
WO2018208707A1 (en) | 2017-05-08 | 2018-11-15 | Neurovia, Inc. | Methods and compositions for treating demyelinating diseases |
KR20200120928A (ko) | 2018-02-14 | 2020-10-22 | 오레곤 헬스 앤드 사이언스 유니버시티 | 소베티롬의 유도체 |
SG11202008251TA (en) | 2018-03-02 | 2020-09-29 | Univ Oregon Health & Science | Amide prodrugs of small molecule nuclear receptor modulators |
US11827596B2 (en) | 2018-12-12 | 2023-11-28 | Autobahn Therapeutics, Inc. | Thyromimetics |
WO2020118564A1 (en) | 2018-12-12 | 2020-06-18 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
WO2020180624A1 (en) | 2019-03-01 | 2020-09-10 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
WO2021108549A1 (en) | 2019-11-29 | 2021-06-03 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
-
2019
- 2019-12-12 US US16/712,815 patent/US11827596B2/en active Active
- 2019-12-12 AU AU2019397067A patent/AU2019397067A1/en not_active Abandoned
- 2019-12-12 CN CN201980091924.8A patent/CN113423684A/zh active Pending
- 2019-12-12 WO PCT/US2019/066066 patent/WO2020123861A1/en unknown
- 2019-12-12 CA CA3122996A patent/CA3122996A1/en active Pending
- 2019-12-12 EP EP19836354.1A patent/EP3894383A1/en active Pending
- 2019-12-12 JP JP2021533331A patent/JP2022513449A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020123861A1 (en) | 2020-06-18 |
EP3894383A1 (en) | 2021-10-20 |
US11827596B2 (en) | 2023-11-28 |
CN113423684A (zh) | 2021-09-21 |
CA3122996A1 (en) | 2020-06-18 |
AU2019397067A1 (en) | 2021-07-22 |
US20200361849A1 (en) | 2020-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022513449A (ja) | 新規な甲状腺模倣物 | |
JP7174709B2 (ja) | ファルネソイドx受容体アゴニストおよびその使用 | |
US20230048992A1 (en) | Novel thyromimetics | |
KR900001511B1 (ko) | 카테콜 유도체 및 그것을 함유하는 중추신경계 퇴행성질환의 진행방지 및 치료제 | |
EP3983384B1 (en) | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis | |
TW201436790A (zh) | 經氘取代之反丁烯二酸酯衍生物類 | |
US11667606B2 (en) | Thyromimetics | |
JP2011026345A (ja) | チロナミン誘導体およびチロナミンアナログならびにこれらを使用する方法 | |
CN110092779B (zh) | 一种取代的苯基化合物及其应用 | |
WO2020118564A1 (en) | Novel thyromimetics | |
JP2023530709A (ja) | 甲状腺様作用剤 | |
JP2023530708A (ja) | 甲状腺様作用剤 | |
WO2021257834A1 (en) | Thyromimetics | |
US20230348364A1 (en) | Isotopic thyromimetic compounds | |
WO2024012532A1 (zh) | 一种gpr139受体激动剂及其制备方法 | |
AU2006325232A1 (en) | Dibenzene derivatives as calcium channel blockers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210713 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221205 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221205 |
|
RD12 | Notification of acceptance of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7432 Effective date: 20230111 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230111 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231204 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240222 |